Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tozuleristide - Blaze Bioscience

Drug Profile

Tozuleristide - Blaze Bioscience

Alternative Names: BLZ-100; Chlorotoxin conjugated to indocyanine green dye - Blaze Bioscience; Chlorotoxin-indocyanine-green-conjugate; CyTP-007; Tumor Paint BLZ-100; Tumour paint

Latest Information Update: 10 Feb 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Blaze Bioscience
  • Developer Blaze Bioscience; Seattle Children's Hospital
  • Class Biological toxins; Drug conjugates; Imaging agents; Indoles; Peptides
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III CNS cancer
  • No development reported Breast cancer; Glioma; Skin cancer; Soft tissue sarcoma

Most Recent Events

  • 08 Feb 2021 Blaze Biosciences and Cedars-Sinai Medical Centre plan a phase II trial for CNS cancer (Diagnosis, In adults, In the elderly) in USA (IV) in April 2021 (NCT04743310)
  • 28 Apr 2020 No recent reports of development identified for phase-I development in Breast-cancer(Diagnosis) in USA (IV, Injection)
  • 28 Apr 2020 No recent reports of development identified for phase-I development in Glioma(Diagnosis, In adolescents, In children, In infants, In adults) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top